# US 8,597,637 B1 · Breast cancer therapy using an engineered respiratory syncytial virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,597,637 B1
- Document ID: US8597637B1
- Status: Granted
- Kind: B1
- Application number: 12/800,585
- Filed: 2010-05-18
- Granted: 2013-12-03
- Earliest claimed: 2010-05-18
- Applicants: Weidong Zhang; Lixian Jiang; Calvin Cao
- Inventors: Weidong Zhang; Lixian Jiang; Calvin Cao
- Web page: https://patentgrep.com/patent/US8597637B1

## CPC

- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61P 15/14: for lactation disorders, e.g. galactorrhoea
- A61P 35/00: Antineoplastic agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2760/18032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/18511: Pneumovirus, e.g. human respiratory syncytial virus
- C12N 2760/18532: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/18543: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention discloses an engineered oncolytic respiratory syncytial virus (RSV), NS1 gene deficient RSV, and its usage to treat breast cancer by killing cancer cells with in vitro and in vivo evidences.

## Claims

### Claim 1

A method to treat breast cancer in a patient in need thereof, comprising:
1) suspending an engineered oncolytic respiratory syncytial virus (RSV) with the NS1 gene deleted in saline or medium, and
2) injecting the RSV suspension into the cancerous tissue, wherein the RSV infects and causes oncolysis to thereby treat the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the RSV is suspended in saline.

### Claim 3 (depends on 1)

The method of claim 1, wherein the RSV is suspended in medium.

### Claim 4

A method to treat breast cancer in a patient in need thereof comprising:
1) suspending an engineered oncolytic respiratory syncytial virus with the NS1 gene deleted, and further comprising the viral NS2, N, M, SH, G, F, M2-1, P, and L genes, in saline or medium, and
2) injecting the engineered RSV suspension into cancerous tissue, wherein the RSV infects and causes oncolysis to thereby treat the patient.

### Claim 5 (depends on 4)

The method of claim 4, wherein the engineered RSV is suspended in saline.

### Claim 6 (depends on 4)

The method of claim 4, wherein the engineered RSV is suspended in medium.